Market Closed -
NSE India S.E.
12:43:49 03/05/2024 BST
|
5-day change
|
1st Jan Change
|
537
INR
|
-3.12%
|
|
-1.29%
|
+62.59%
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
37,259
|
27,735
|
19,933
|
27,214
|
34,473
|
19,908
|
Enterprise Value (EV)
1 |
37,238
|
29,335
|
23,410
|
34,445
|
41,053
|
27,699
|
P/E ratio
|
35.6
x
|
24.7
x
|
12.8
x
|
18.4
x
|
54.7
x
|
-61.3
x
|
Yield
|
0.15%
|
0.29%
|
0.45%
|
0.33%
|
0.28%
|
-
|
Capitalization / Revenue
|
4.72
x
|
3.78
x
|
2.19
x
|
3.02
x
|
3.01
x
|
1.89
x
|
EV / Revenue
|
4.72
x
|
4
x
|
2.58
x
|
3.82
x
|
3.58
x
|
2.63
x
|
EV / EBITDA
|
24.7
x
|
19
x
|
10.9
x
|
20.2
x
|
20.7
x
|
32
x
|
EV / FCF
|
-38.1
x
|
-13.1
x
|
-10.5
x
|
-8.55
x
|
-17.5
x
|
-25.1
x
|
FCF Yield
|
-2.63%
|
-7.62%
|
-9.56%
|
-11.7%
|
-5.72%
|
-3.98%
|
Price to Book
|
3.49
x
|
2.32
x
|
1.5
x
|
1.84
x
|
1.89
x
|
1.12
x
|
Nbr of stocks (in thousands)
|
80,127
|
81,527
|
81,527
|
81,527
|
86,802
|
86,802
|
Reference price
2 |
465.0
|
340.2
|
244.5
|
333.8
|
397.2
|
229.4
|
Announcement Date
|
28/08/18
|
29/08/19
|
15/08/20
|
04/09/21
|
05/09/22
|
05/09/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
7,894
|
7,337
|
9,082
|
9,016
|
11,469
|
10,517
|
EBITDA
1 |
1,509
|
1,545
|
2,144
|
1,709
|
1,981
|
865.4
|
EBIT
1 |
1,148
|
1,141
|
1,723
|
1,188
|
1,204
|
-54
|
Operating Margin
|
14.54%
|
15.55%
|
18.97%
|
13.17%
|
10.5%
|
-0.51%
|
Earnings before Tax (EBT)
1 |
1,368
|
1,357
|
1,881
|
1,951
|
1,023
|
-382.8
|
Net income
1 |
1,052
|
1,123
|
1,562
|
1,478
|
606.6
|
-324.8
|
Net margin
|
13.33%
|
15.3%
|
17.19%
|
16.39%
|
5.29%
|
-3.09%
|
EPS
2 |
13.07
|
13.77
|
19.15
|
18.13
|
7.260
|
-3.741
|
Free Cash Flow
1 |
-978.2
|
-2,234
|
-2,238
|
-4,028
|
-2,348
|
-1,104
|
FCF margin
|
-12.39%
|
-30.46%
|
-24.64%
|
-44.67%
|
-20.47%
|
-10.5%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
0.7000
|
1.000
|
1.100
|
1.100
|
1.100
|
-
|
Announcement Date
|
28/08/18
|
29/08/19
|
15/08/20
|
04/09/21
|
05/09/22
|
05/09/23
|
Fiscal Period: March |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
---|
Net sales
1 |
1,912
|
2,080
|
2,374
|
2,953
|
2,723
|
3,406
|
2,612
|
2,629
|
2,625
|
EBITDA
1 |
209.7
|
262.5
|
318.8
|
531.6
|
450.9
|
737.3
|
205.7
|
122
|
312.9
|
EBIT
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
13/02/21
|
31/05/21
|
14/08/21
|
29/10/21
|
08/02/22
|
23/05/22
|
11/08/22
|
11/11/22
|
14/02/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
1,599
|
3,477
|
7,231
|
6,579
|
7,791
|
Net Cash position
1 |
21.2
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
1.035
x
|
1.622
x
|
4.23
x
|
3.322
x
|
9.002
x
|
Free Cash Flow
1 |
-978
|
-2,234
|
-2,238
|
-4,028
|
-2,348
|
-1,104
|
ROE (net income / shareholders' equity)
|
9.97%
|
9.65%
|
12.3%
|
10.5%
|
3.7%
|
-1.72%
|
ROA (Net income/ Total Assets)
|
4.78%
|
4.59%
|
5.99%
|
3.21%
|
2.73%
|
-0.12%
|
Assets
1 |
22,039
|
24,478
|
26,072
|
46,059
|
22,200
|
278,051
|
Book Value Per Share
2 |
133.0
|
147.0
|
163.0
|
181.0
|
210.0
|
205.0
|
Cash Flow per Share
2 |
9.030
|
4.200
|
5.440
|
15.10
|
3.900
|
2.460
|
Capex
1 |
1,380
|
3,000
|
3,493
|
3,542
|
3,318
|
2,725
|
Capex / Sales
|
17.48%
|
40.89%
|
38.46%
|
39.29%
|
28.93%
|
25.91%
|
Announcement Date
|
28/08/18
|
29/08/19
|
15/08/20
|
04/09/21
|
05/09/22
|
05/09/23
|
|
1st Jan change
|
Capi.
|
---|
| +21.85% | 546B | | -4.77% | 359B | | +16.97% | 323B | | +5.69% | 290B | | +13.68% | 234B | | +3.65% | 198B | | -11.12% | 194B | | +8.08% | 167B | | -3.40% | 157B |
Other Pharmaceuticals
|